Precise Cas9 targeting enables genomic mutation prevention

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 14, 2018, Pages 3669-3673

  Chavez, Alejandro ^a,b,c   Pruitt, Benjamin W ^b   Tuttle, Marcelle ^b   Shapiro, Rebecca S ^b,d,e,f   Cecchi, Ryan J ^b   Winston, Jordan ^b   Turczyk, Brian M ^b   Tung, Michael ^b   Collins, James J ^b,d,e   Church, George M ^b,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Massachusetts Institute of Technology   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f UNIVERSITY OF GUELPH   (Canada)

Author keywords

Cas9; Mutation prevention; Synthetic biology; TgRNA; Tuned gRNA

Indexed keywords

BETA LACTAMASE TEM 1; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; GUIDE RNA; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; ESCHERICHIA COLI; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL TRACT; GENE MUTATION; IN VIVO STUDY; METHODOLOGY; MISMATCH REPAIR; MOUSE; MUTATION RATE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BACTERIAL GENOME; CRISPR CAS SYSTEM; GENETICS; GENOMICS; METABOLISM; MUTATION; PROCEDURES;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CRISPR-CAS SYSTEMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENOME, BACTERIAL; GENOMICS; MICE; MUTATION; RIFAMPIN; RNA, GUIDE;

EID: 85044871024     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1718148115     Document Type: Article

References (48)

1. Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: Is it possible to reverse resistance? Nat Rev Microbiol 8:260–271.
2. Watson IR, Takahashi K, Futreal PA, Chin L (2013) Emerging patterns of somatic mutations in cancer. Nat Rev Genet 14:703–718.
3. Köser CU, Ellington MJ, Peacock SJ (2014) Whole-genome sequencing to control antimicrobial resistance. Trends Genet 30:401–407.
4. Vockley JG, Niederhuber JE (2015) Diagnosis and treatment of cancer using genomics. BMJ 350:h1832.
5. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821.
6. Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109:E2579–E2586.
7. Deltcheva E, et al. (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471:602–607.
8. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA (2014) DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507:62–67.
9. Semenova E, et al. (2011) Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci USA 108:10098–10103.
10. Fu Y, et al. (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31:822–826.
11. Hsu PD, et al. (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31:827–832.
12. Pattanayak V, et al. (2013) High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31:839–843.
13. Mali P, et al. (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31:833–838.
14. Cho SW, et al. (2014) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132–141.
15. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32: 677–683.
16. Wu X, et al. (2014) Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32:670–676.
17. Frock RL, et al. (2015) Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 33:179–186.
18. Tsai SQ, et al. (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187–197.
19. Wang X, et al. (2015) Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33:175–178.
20. Kim D, et al. (2015) Digenome-seq: Genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237–243, 1, 243.
21. Ran FA, et al. (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380–1389.
22. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32:279–284.
23. Guilinger JP, Thompson DB, Liu DR (2014) Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32: 577–582.
24. Tsai SQ, et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32:569–576.
25. Wyvekens N, Topkar VV, Khayter C, Joung JK, Tsai SQ (2015) Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing. Hum Gene Ther 26:425–431.
26. Slaymaker IM, et al. (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–88.
27. Kleinstiver BP, et al. (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–495.
28. Doench JG, et al. (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184–191.
29. Chen JS, et al. (2017) Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature 550:407–410.
30. Siegel EC, Bryson V (1967) Mutator gene of Escherichia coli B. J Bacteriol 94:38–47.
31. Cox EC (1976) Bacterial mutator genes and the control of spontaneous mutation. Annu Rev Genet 10:135–156.
32. Drawz SM, Bonomo RA (2010) Three decades of β-lactamase inhibitors. Clin Microbiol Rev 23:160–201.
33. Hou Z, et al. (2013) Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 110:15644–15649.
34. Esvelt KM, et al. (2013) Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10:1116–1121.
35. Shi R, Itagaki N, Sugawara I (2007) Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev Med Chem 7:1177–1185.
36. Schatz A, Bugle E, Waksman S (1944) Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Exp Biol Med 55:66–69.
37. Timms AR, Steingrimsdottir H, Lehmann AR, Bridges BA (1992) Mutant sequences in the rpsL gene of Escherichia coli B/r: Mechanistic implications for spontaneous and ultraviolet light mutagenesis. Mol Gen Genet 232:89–96.
38. Sensi P, Greco AM, Ballotta R (1959–1960) Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot Annu 7:262–270.
39. Jin DJ, Gross CA (1988) Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 202:45–58.
40. Kleinstiver BP, et al. (2015) Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481–485.
41. DiCarlo JE, et al. (2013) Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 41:4336–4343.
42. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA (2013) RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31:233–239.
43. Citorik RJ, Mimee M, Lu TK (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32:1141–1145.
44. Bikard D, et al. (2014) Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:1146–1150.
45. van Overbeek M, et al. (2016) DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks. Mol Cell 63:633–646.
46. Ipsaro JJ, et al. (2017) Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. PLoS One 12:e0172177.
47. Zetsche B, et al. (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163:759–771.
48. Shmakov S, et al. (2015) Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell 60:385–397.